Alterations in Homologous Recombination-Related Genes and Distinct Platinum Response in Metastatic Triple-Negative Breast Cancers: A Subgroup Analysis of the ProfiLER-01 Trial.
BRCA
DNA repair
HRR genes
TNBC
homologous recombination
platinum-based chemotherapy
triple-negative breast cancer
Journal
Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269
Informations de publication
Date de publication:
27 Sep 2022
27 Sep 2022
Historique:
received:
31
07
2022
revised:
19
09
2022
accepted:
22
09
2022
entrez:
27
10
2022
pubmed:
28
10
2022
medline:
28
10
2022
Statut:
epublish
Résumé
a specific subset of metastatic triple-negative breast cancers (mTNBC) is characterized by homologous recombination deficiency (HRD), leading to enhanced sensitivity to platinum-based chemotherapy. Apart from mutations in next-generation sequencing and promoter methylation of mutations in
Sections du résumé
BACKGROUND
BACKGROUND
a specific subset of metastatic triple-negative breast cancers (mTNBC) is characterized by homologous recombination deficiency (HRD), leading to enhanced sensitivity to platinum-based chemotherapy. Apart from mutations in
METHODS
METHODS
next-generation sequencing and promoter methylation of
RESULTS
RESULTS
mutations in
Identifiants
pubmed: 36294734
pii: jpm12101595
doi: 10.3390/jpm12101595
pmc: PMC9604780
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : French National Cancer Institute
ID : DGOS-INCA-4664
Organisme : Bpifrance
ID : E8983-PREDICTIV
Organisme : LABEX DevweCAN
ID : ANR-10-LABX-0061
Organisme : CSRD VA
ID : 1
Pays : United States
Organisme : CSRD VA
ID : 1
Pays : United States
Organisme : EURACAN
ID : EU project 739521
Références
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Nat Rev Clin Oncol. 2022 Feb;19(2):91-113
pubmed: 34754128
Ann Oncol. 2021 Jan;32(1):103-112
pubmed: 33091561
Oncotarget. 2017 Sep 15;8(47):83063-83074
pubmed: 29137324
J Clin Oncol. 2015 Jan 1;33(1):13-21
pubmed: 25092775
Eur J Cancer. 2021 Dec;159:283-295
pubmed: 34837859
Breast. 2019 Jun;45:15-21
pubmed: 30818144
N Engl J Med. 2017 Aug 10;377(6):523-533
pubmed: 28578601
Nat Genet. 2017 Oct;49(10):1476-1486
pubmed: 28825726
Ann Oncol. 2021 Dec;32(12):1475-1495
pubmed: 34678411
Cancers (Basel). 2022 Feb 21;14(4):
pubmed: 35205846
Am J Clin Pathol. 2017 Oct 01;148(4):296-307
pubmed: 28967952
Ann Oncol. 2018 Dec 1;29(12):2341-2347
pubmed: 30335131
Ann Oncol. 2019 May 1;30(5):757-765
pubmed: 30865223
Clin Cancer Res. 2016 Aug 1;22(15):3764-73
pubmed: 26957554
NPJ Breast Cancer. 2022 Aug 20;8(1):95
pubmed: 35987766
Nat Med. 2019 Oct;25(10):1526-1533
pubmed: 31570822
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Ann Oncol. 2021 Feb;32(2):240-249
pubmed: 33242536
Nat Med. 2018 May;24(5):628-637
pubmed: 29713086
J Clin Oncol. 2015 Jun 10;33(17):1895-901
pubmed: 25847929
Cancers (Basel). 2022 Feb 23;14(5):
pubmed: 35267439
Methods Mol Biol. 2011;780:277-91
pubmed: 21870267
Ann Oncol. 2018 Mar 1;29(3):654-660
pubmed: 29293876
Lancet Oncol. 2014 Jun;15(7):747-56
pubmed: 24794243
J Clin Oncol. 2015 Jun 10;33(17):1902-9
pubmed: 25847936
Genet Med. 2018 Dec;20(12):1677-1686
pubmed: 29988077
J Mol Diagn. 2017 Jan;19(1):4-23
pubmed: 27993330
Cancer J. 2021 Jan-Feb 01;27(1):8-16
pubmed: 33475288
N Engl J Med. 2021 Jun 24;384(25):2394-2405
pubmed: 34081848
N Engl J Med. 2018 Aug 23;379(8):753-763
pubmed: 30110579
Clin Breast Cancer. 2021 Oct;21(5):383-390
pubmed: 33781662